The anti-abortion movement's patience with the Food and Drug Administration (FDA) is wearing thin following the agency’s recent approval of a second generic version of mifepristone, one of two drugs taken for a medication abortion.

President Trump repeatedly pledged during the campaign last year that he would leave abortion policy to the states, but anti-abortion advocates and lawmakers have been pushing him to go further and sharply restrict the availability of mifepristone.

So far, that hasn’t happened.

A letter sent to a group of GOP state attorneys general in September confirmed that the FDA was reviewing evidence about the safety of mifepristone to investigate how it can be safely dispensed.

“This Administration will ensure that women’s health is properly protected by thoroughly investigating the circumstances under which mifepristone can be safely dispensed,” Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary wrote in the letter, sent Sept. 19.

The disclosure garnered some cautious optimism from the right, as lawmakers and activists said they hoped the FDA would soon act to roll back regulatory changes that made mifepristone easier to access.

But then came the news that Evita Solutions would soon become the third company in the U.S. approved to manufacture and sell mifepristone.

"FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA," Sen. Josh Hawley (R-Mo.) wrote on social platform X.........

© The Hill